Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07449702) titled 'An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis' on Feb. 26.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Oruka Therapeutics, Inc.

Condition: Plaque Psoriasis

Intervention: Drug: ORKA-001

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: February 23, 2026

Target Sample Size: 80

Countries of Recruitment: United States Canada United States

To know more, visit https://clinicaltrials.gov/study/NCT07449702

Published...